TCR2 Therapeutics
675 West Kendall Street
Suite I
Cambridge
Massachusetts
02142
United States
Tel: 617-475-8469
Website: http://www.tcr2.com/
Email: info@tcr2.com
About TCR2 Therapeutics
At TCR2 Therapeutics we have a bold vision – to cure cancer by using our immune system in a more natural way. We have developed a unique proprietary TRuC™ platform based on T cell receptor fusion constructs that have the advantage of employing the full signaling power inherent to a complete T cell receptor (TCR). Our TRuC™ variants can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. We have demonstrated activity against both hematological and solid tumor targets in preclinical models and we believe TRuC™-T cells will serve as the engine for novel therapies which we are quickly advancing towards the clinic.The company was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. We have since assembled a world class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA.
YEAR FOUNDED:
2015
LEADERSHIP:
Founder: Dr. Patrick Baeuerle
CEO: Garry Menzel, PhD and MBA
CSO: Robert Hofmeister, PhD
Acting CSO: John Pallies
Chief IP Counsel: Gregory Sieczkiewicz, PhD and JD
Head of Corporate Development: Helen Ho, PhD
Manager of Human Reources & Office Dynamics: Eva Quinn
TECHNOLOGY:
Please click here for TCR2 Therapeutics's technology.
116 articles about TCR2 Therapeutics
-
TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors
10/25/2021
TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, announced a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate gavo-cel in combination with Opdivo® and Yervoy® in its planned Phase 2 clinical trial in treatment refractory mesothelin-expressing solid tumors.
-
Merck entered into collaborations with three different companies as it continues to assess Keytruda in combination with experimental drugs in different cancer indications.
-
TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day
10/20/2021
TCR 2 Therapeutics Inc. today unveiled new programs and provided highlights from its emerging TRuC pipeline programs during its first virtual R&D Day.
-
TCR² Therapeutics to Host R&D Day on October 20, 2021
10/13/2021
TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced that it will host a virtual R&D Day for analysts and investors at 8:00a.m. ET on Wednesday, October 20, 2021.
-
TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy
10/5/2021
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the e-poster presentation of new preclinical data at the American Association for Cancer Research (AACR) Virtual Special Conference on Tumor Immunology and Immunotherapy, taking place October 5-6, 2021.
-
Clinical Catch-Up: September 13-17
9/20/2021
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look. -
TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors
9/17/2021
TCR2 Therapeutics Inc. today announced positive interim results from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors.
-
The European Society for Medical Oncology Congress 2021 runs from September 16–21, 2021. Here’s a preview of some of the presentations at the meeting.
-
TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid Tumors
9/13/2021
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company will host a conference call and live audio webcast on Friday, September 17, 2021 at 9:00am E.T. to discuss extended data from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors.
-
TCR² Therapeutics to Present at the H.C. Wainwright Global Investment Conference
9/7/2021
TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced that Ian Somaiya, Chief Financial Officer of TCR2 Therapeutics, will present an update on Company progress at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13th at 7:00AM E.T.
-
TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma
9/2/2021
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Orphan Drug Designation (ODD) to gavo-cel for the treatment of cholangiocarcinoma.
-
TCR² Therapeutics Announces Renowned Translational Medicine Leader Priti Hegde Joins Its Board of Directors
8/26/2021
TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced the appointment of Priti Hegde, Ph.D., to its Board of Directors.
-
TCR² Therapeutics Announces Upcoming Medical Meetings Update - Aug 17, 2021
8/17/2021
TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced that their interim update on the Phase 1/2 clinical trial of gavo-cel will be featured in the official Press Programme at the European Society for Medical Oncology.
-
TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
8/5/2021
TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.
-
TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing Veteran Peter Olagunju as Chief Technical Officer
7/20/2021
TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients with solid tumors, announced the appointment of Peter Olagunju as Chief Technical Officer where he will oversee process development, manufacturing, quality control and technical operations for the Company’s TRuC-T cell programs and emerging pipeline.
-
TCR² Therapeutics to Participate in Two Upcoming Conferences in June 2021
5/26/2021
TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, announced that management will participate at two upcoming conferences in June using a virtual platform.
-
TCR² Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
5/13/2021
TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update.
-
Fueled by billions of dollars invested by the federal government to battle the ongoing COVID-19 pandemic, companies across the BioCapital region have expanded their footprint and number of employees.
-
TCR² Therapeutics to Present at the Truist Securities Life Sciences Summit
4/29/2021
TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021 at 11:20am E.T. using a virtual platform.
-
TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting
4/10/2021
TCR2 Therapeutics Inc. announced that clinical and translational data from the dose escalation portion of the Company’s Phase 1/2 clinical trial of gavo-cel in patients with treatment refractory mesothelin-expressing solid tumors will be presented at the American Association for Cancer Research Virtual Annual Meeting